Klufas Michael A, Wolden Suzanne L, Bohle George C, Wexler Leonard H, Abramson David H
*Department of Ophthalmology, Weill Cornell Medical College; †Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York; ‡Implant and Prosthodontic Associates, Oklahoma City, Oklahoma; and §Department of Pediatrics, and ‖Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, U.S.A.
Ophthalmic Plast Reconstr Surg. 2015 Jul-Aug;31(4):e89-91. doi: 10.1097/IOP.0000000000000111.
A 6-year-old boy initially presented to an outside hospital with a right orbital mass with biopsy positive for translocation involving EWS RNA-binding protein 1 gene and imaging consistent with primary extraskeletal Ewing sarcoma (ES). There was no evidence of metastatic disease. Patient underwent gross tumor resection and adjuvant chemotherapy (VAdriaC/IE) followed by postoperative 45-Gy proton beam radiation. After 19 months, a solitary in-field local recurrence occurred, which was unsuccessfully surgically resected. Thereafter, treatment commenced with irinotecan and temozolomide, and the patient presented to the center of the authors. MRI showed locally recurrent disease without evidence of metastatic disease. Right orbital exenteration was performed, and an orbital mold was fashioned to deliver brachytherapy. There were no complications. The patient had no evidence of recurrent disease at 37-month follow up. This is the first report of orbital implant brachytherapy for recurrent primary ES of the orbit, and an additional report of primary extraskeletal ES of the orbit, which is a rare primary orbital tumor.
一名6岁男孩最初因右眼眶肿块就诊于外院,活检显示涉及EWS RNA结合蛋白1基因的易位呈阳性,影像学检查结果与原发性骨外尤文肉瘤(ES)相符。无转移疾病证据。患者接受了肿瘤全切及辅助化疗(VAdriaC/IE),随后进行了术后45 Gy的质子束放疗。19个月后,出现孤立的野内局部复发,手术切除未成功。此后,开始使用伊立替康和替莫唑胺进行治疗,患者随后就诊于作者所在中心。MRI显示局部复发病灶,无转移疾病证据。进行了右眼眶内容剜除术,并制作了眼眶模具以进行近距离放疗。无并发症发生。在37个月的随访中,患者无复发病灶证据。这是首例关于眼眶植入近距离放疗治疗复发性眼眶原发性ES的报告,也是另一例眼眶原发性骨外ES的报告,眼眶原发性骨外ES是一种罕见的原发性眼眶肿瘤。